SCHEMBL211009

SCHEMBL211009

CC(C)(C)OC(=O)NC1CCCN(C(=O)c2ccc(-c3cc(Cl)c(C(C4CCCCC4)C4CCNC4=O)c(Cl)c3)cc2)C1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1L1 Q9UHC9 2/20 0.41
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
USP30 Q70CQ3 1/20 0.40
CFTR P13569 1/20 0.39
PADI4 Q9UM07 3/20 0.39
HDAC4 P56524 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
BTK Q06187 1/20 0.38
BRD4 O60885 2/20 0.37
KMT2A Q03164 1/20 0.37
AURKA O14965 3/20 0.37
PDPK1 O15530 3/20 0.37
AURKB Q96GD4 3/20 0.37
PARP1 P09874 1/20 0.37
CNR1 P21554 1/20 0.36
CNR2 P34972 1/20 0.36
KDM6A O15550 1/20 0.36
KDM4D Q6B0I6 1/20 0.36
NAMPT P43490 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL210631 0.85 MEN1 (0.48) NPC1L1USP30CFTRHDAC4KMT2A
SCHEMBL209052 0.81 HDAC4 (0.48) USP30HDAC4HDAC6KMT2APARP1
SCHEMBL4551238 0.79 PDE5A (0.41) KMT2A
SCHEMBL4189838 0.78 CHRNA7 (0.45) KMT2ACNR2
SCHEMBL210020 0.78 PDE5A (0.40) BTKKMT2APARP1
SCHEMBL4180949 0.78 BMPR1B (0.43) KMT2A
SCHEMBL4194240 0.78 SPR (0.38) KMT2ANAMPT
SCHEMBL209390 0.77 P2RX7 (0.40) KMT2A
SCHEMBL211008 0.76 NPC1L1 (0.42) NPC1L1CA1CA2USP30CFTR
SCHEMBL3320831 0.76 CA1 (0.58) NPC1L1CA1CA2USP30PADI4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2016047-B1 BIPHENYL AMIDE LACTAM DERIVATIVES AS INHIBITORS OF 11- BETA-HYDROXYSTEROID DEHYDROGENASE 1 LILLY CO ELI (US) 2013-08-28 EP disclosed
US-8088776-B2 Biphenyl amide lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 ELI LILLY AND COMPANY (US) 2012-01-03 US disclosed
US-20090156571-A1 BIPHENYL AMIDE LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 ELI LILLY AND COMPANY 2009-06-18 US disclosed
EP-2016047-A1 BIPHENYL AMIDE LACTAM DERIVATIVES AS INHIBITORS OF 11- BETA-HYDROXYSTEROID DEHYDROGENASE 1 ELI LILLY AND COMPANY (US) 2009-01-21 EP disclosed
WO-2007124337-A1 BIPHENYL AMIDE LACTAM DERIVATIVES AS INHIBITORS OF 11- BETA-HYDROXYSTEROID DEHYDROGENASE 1 ELI LILLY AND COMPANY (US) 2007-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156571-A1 BIPHENYL AMIDE LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 HSD11B1, HSD17B1, HSD11B2 NPC1L1 1280/4885CA1 491/4885CA2 2513/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.